FIPRA International SRL
Budget
Not declared
EP Access
36
accredited persons
Staff
75
70.25 FTE
EU Grants
None
Mission & Goals
Founded in 2000, FIPRA International is a leading European and international public affairs consultancy advising clients on a range of government relations and regulatory policy issues. FIPRA International has relationships with a range of other consultancies across Europe and globally: the wider FIPRA network extends to over 50 countries both in Europe and internationally. FIPRA’s business focus is on the provision of advice and assistance in “public affairs” also termed “government relations”. We advise companies and non-corporate clients on how best to engage with government and public institutions on questions of policy, legislation and regulation that concern them.
EU Legislative Interests
FIPRA’s business focus is on the provision of advice and assistance in “public affairs” also termed “government relations”. We advise companies and non-corporate clients on how best to engage with government and public institutions on questions of policy, legislation and regulation that concern them. In Europe, much of our work is undertaken with the institutions of the European Union. Our entry on the joint European Commission and European Parliament Register relates to our work undertaken on behalf of clients in connection with the EU institutions. Specific EU legislative proposals and/or policies being followed vary according to the interests of our clients, but in the course of 2022 these have included: EU environmental policy, including the European Green Deal and Roadmap; public consultations by DG COMP on aspects of EU competition policy (mergers, anti-trust, state aid); public consultations by DG GROW, DG CNECT and DG MOVE on aspects of EU mobility and connected intelligent transport systems (C-ITS) and related data aspects; EU policies on health, wellbeing and pharmaceutical policy, including the EU Roadmap on pharmaceutical strategy; EU chemicals legislation REACH, authorisation of substances; EU trade policy, in particular EU-US (TTIP) and EU-UK negotiations for a post-Brexit EU-UK trade agreement; EU data and technology policy, including on access to data and data-sharing, and the proposed White Paper on artificial intelligence policy. FIPRA is also registered on the EU Health Policy Platform (see: https://ec.europa.eu/health/interest_groups/policy_platform_en) representing HIV Outcomes: https://hivoutcomes.eu
Communication Activities
FIPRA acts as the secretariat to the RWE4Decisions initiative, facilitating multi-stakeholder discussions between Health Technology Assessment (HTA) bodies, payers, clinicians, patient representatives, researchers, industry and academics. The RWE4Decisions stakeholder group authored a paper, identifying how Real-World Evidence (RWE) can support HTA/payer decisions about highly innovative technologies. In 2021, the RWE4Decisions initiative was enabled by the sponsorship of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Astra Zeneca, Gilead Sciences, Amgen and Roche. See: https://rwe4decisions.com/
Interests Represented
Advances interests of their clients
Member Of
BritCham - British Chamber of Commerce in Belgium Spanish Chamber of Commerce Competition Law Forum (CLF) European Policy Centre (EPC) European Public Affairs Consultancies Association (EPACA) European Risk Forum (ERF) 1 1 FIPRA International is a member of the ERF, a not-for-profit think tank with a focus on regulatory risk, better regulation, impact assessment, the best use of science and related matters. FIPRA offers pro-bono support to the ERF.
Organisation Members
FIPRA acts as the secretariat of HIV Outcomes, a multi-stakeholder initiative that brings together patient organisations, medical professionals, academics, public institutions and the private sector to align on a new policy and clinical agenda to address the crucial unmet needs of people living with HIV across Europe. HIV Outcomes engages with policy makers at the European and national level to advocate for the implementation of policy changes to improve the long-term health outcomes and quality of life of people living with HIV. The initiative is enabled by sponsorship provided by Gilead Sciences and ViiV Healthcare. See: https://hivoutcomes.eu FIPRA acts as the secretariat of the HIV Prevention Alliance, a pan-European, multi-stakeholder initiative uniting communities most affected by HIV as well as clinicians, researchers, and industry. Launched in April 2025, the Alliance advocates for political commitment to comprehensive HIV and STI combination prevention and for accelerating progress toward SDG 3.3: ending AIDS as a public health threat by 2030. The initiative is enabled by sponsorship provided by Gilead Sciences, Merck Sharp & Dohme (MSD), AND ViiV Healthcare. See: https://hivpreventionalliance.eu
Commissioner Meetings
No recorded meetings with EU commissioners.